Ideaya, Pfizer expand clinical collaboration

By The Science Advisory Board staff writers

September 24, 2020 -- Ideaya Biosciences has expanded its clinical trial collaboration and supply agreement with Pfizer for the combination study of IDE196, a protein kinase C inhibitor, and crizotinib, a c-MET inhibitor.

The new study will evaluate the combination therapy in patients with solid tumors that have GNAQ or GNA11 mutations, including metastatic uveal melanoma, skin melanoma, lung cancer, and colorectal cancer.

Ideaya is already evaluating IDE196 in combination with binimetinib. The clinical study for IDE196 and binimetinib began in June 2020 and is targeting to start evaluating the combination of IDE196 with crizotinib, for which Pfizer holds exclusive worldwide rights, in late 2020 to early 2021. Also, Ideaya is evaluating IDE196 as a monotherapy, which has recently entered phase II studies.

Ideaya and Pfizer have formed a joint development committee for clinical trials. Ideaya will sponsor the study and Pfizer will provide the crizotinib drug supply. If clinical data from the collaboration studies could be used to obtain regulatory approvals or label changes, Ideaya and Pfizer will enter into good faith negotiations to determine a regulatory submission strategy.

If you like this content, please share it with a colleague!

Related Reading

Pfizer to manufacture Vivet's gene therapy
Vivet Therapeutics and Pfizer have entered into a manufacturing agreement where Pfizer will provide clinical supply for a phase I/II clinical trial evaluating...

Pfizer begins phase I study of COVID-19 drug targeting main protease
Pfizer has begun a phase IB clinical trial to evaluate the safety of an investigational COVID-19 drug candidate, PF-00835321, that blocks the main protease...

Pfizer, BioNTech release preclinical data, talk with EU about COVID-19 vaccine
Preclinical data have demonstrated the ability of BNT162b2, Pfizer and BioNTech's COVID-19 vaccine, to protect against infection. The companies are also...

Early trials show potential of Pfizer COVID-19 vaccine
Pharmaceutical giant Pfizer is making progress on BNT162b1, a COVID-19 vaccine candidate that is undergoing development and for which the U.S. government...

Pfizer to manufacture remdesivir for Gilead
Pfizer has inked a multiyear agreement with Gilead Sciences to manufacture and supply Gilead's investigational antiviral drug remdesivir, joining other...